OXURION (EBR:OXUR) | WebDisclosure

Basculer en Français

11305	Companies
251239	Keywords
180296	Articles
137085	Press releases

Home
Companies
OXURION

PRESS RELEASE

published on 10/03/2025 at 18:00, 1 year 1 month ago

Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
Atlas Special Opportunities, LLC heeft 4 converteerbare obligaties van Oxurion geconverteerd, wat resulteerde in EUR 100.000 aan kapitaalverhoging. Oxurion NV publiceert informatie over de uitgifte van nieuwe aandelen in het kader van een kapitaaltoezegging met Atlas Special Opportunities, LLC

Kapitaalverhoging Atlas Special Opportunities Aandelen Oxurion Converteerbare Obligaties
PRESS RELEASE

published on 10/03/2025 at 18:00, 1 year 1 month ago

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Atlas Special Opportunities, LLC converts 4 convertible bonds in Oxurion, leading to EUR 100,000 capital increase. Oxurion issues 5,990,086 new ordinary shares as part of EUR 20m Capital Commitment with Atlas. Company's total outstanding shares now 56,367,609

Shares Convertible Bonds Capital Increase Atlas Special Opportunities Oxurion
BRIEF

published on 10/02/2025 at 18:05, 1 year 1 month ago

Oxurion reçoit une notification de transparence d'Atlas Special Opportunities II LLC

Actions Transparence Pharmaceutique Atlas Special Opportunities Oxurion
BRIEF

published on 10/02/2025 at 18:05, 1 year 1 month ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Actions Transparency Pharmaceutical Atlas Special Opportunities Oxurion
PRESS RELEASE

published on 10/02/2025 at 18:00, 1 year 1 month ago

Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
Oxurion NV kondigt ontvangst van transparantiekennisgeving aan en verwerft meerderheidsbelangen in Europese farmaceutische onderaannemers

Transparantiekennisgeving Oxurion NV België Meerderheidsbelangen Farmaceutische Onderaannemers
PRESS RELEASE

published on 10/02/2025 at 18:00, 1 year 1 month ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV received a transparency notification from Atlas Special Opportunities II, LLC regarding changes in shareholding. The company specializes in acquiring stakes in European pharmaceutical subcontractors. Risks associated with forward-looking statements and planned investments in digital assets are highlighted

Forward-looking Statements Digital Assets Transparency Notification Oxurion NV Pharmaceutical Subcontractors
BRIEF

published on 09/30/2025 at 18:05, 1 year 1 month ago

Résultats Semestriels 2025 d'Oxurion : Analyse Financière et Opérationnelle

Résultats Financiers Actifs Numériques Prévisions Oxurion Sous-traitants Pharmaceutiques
BRIEF

published on 09/30/2025 at 18:05, 1 year 1 month ago

Oxurion 2025 Half-Year Results: Financial and Operational Analysis

Financial Results Digital Assets Forecasts Oxurion Pharmaceutical Subcontractors
PRESS RELEASE

published on 09/30/2025 at 18:00, 1 year 1 month ago

Oxurion maakt halfjaarresultaten 2025 bekend
Oxurion NV, ein in Leuven ansässiges biofarmazeutisches Unternehmen, veröffentlicht eine finanzielle und geschäftliche Halbjahresupdate. Weitere Informationen unter www.oxurion.com

Investitionen Oxurion NV Leuven Biofarmazeutisch Halbjahresupdate
PRESS RELEASE

published on 09/30/2025 at 18:00, 1 year 1 month ago

Oxurion publie ses résultats du premier semestre 2025
Oxurion NV a publié aujourd'hui ses résultats financiers et opérationnels pour le semestre clos le 30 Juin 2025. Consultez le rapport dans la section 'Investors' du site Web de la Société

Résultats Financiers Investissements Rapport Semestriel Oxurion NV Opérationnels

Accesswire

Published on 11/10/2026 at 08:00, 2 hours 47 minutes ago

PEL 82 - QatarEnergy to Acquire 25% Participating Interest from Chevron
Published on 11/10/2026 at 02:45, 8 hours 2 minutes ago

Presentation to Zurich Precious Metals Summit
Published on 11/09/2026 at 23:10, 11 hours 37 minutes ago

Ur-Energy Reports Third Quarter 2026 Results
Published on 11/09/2026 at 23:00, 11 hours 47 minutes ago

LNG Energy Group Announces Issuance of Third Partial Revocation Order and Proposed Shares-for-Debt Settlement
Published on 11/09/2026 at 22:32, 12 hours 15 minutes ago

Announces Extension for Closing of Private Placement of Convertible Promissory Notes

View all ACCESSWIRE

EQS Group

Published on 11/10/2026 at 10:12, 34 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 11/10/2026 at 10:09, 38 minutes ago

EQS-Adhoc: Emerald Horizon AG plans to raise approximately EUR 135 million in equity by 2028 and resolves first cash capital increase
Published on 11/10/2026 at 10:08, 38 minutes ago

Geek+ Unveils 24/7 Warehouse Autonomy Plan to Advance Self-Optimizing, Around-the-Clock Operation
Published on 11/10/2026 at 10:05, 42 minutes ago

Bedsure Brings Warmth and Comfort Home This Black Friday and Cyber Monday
Published on 11/10/2026 at 09:45, 1 hour 2 minutes ago

TRATON GROUP’s International Motors receives U.S. content approval from U.S. Department of Commerce

Les Echos

Published on 11/10/2026 at 07:00, 3 hours 47 minutes ago

bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
Published on 11/10/2026 at 07:00, 3 hours 47 minutes ago

bioMérieux obtient l’autorisation 510(k) de la FDA américaine et le marquage CE selon l’IVDR pour VITEK® PRO, son nouvel instrument automatisé d’identification et d’antibiogramme contribuant à la lutte contre l’antibiorésistance
Published on 11/09/2026 at 18:30, 16 hours 17 minutes ago

Air Liquide has successfully issued a CHF 390 million multi-tranche bond
Published on 11/09/2026 at 18:30, 16 hours 17 minutes ago

Air Liquide a réalisé avec succès une émission obligataire multi-tranches de 390 millions de CHF
Published on 11/09/2026 at 17:45, 17 hours 2 minutes ago

Weekly share buyback

View all LES ECHOS COMFI WIRE